Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Eculizumab Add-On Therapy in the Acute Phase of Neuromyelitis Optica Spectrum Disorder: A Multicenter Prospective Real-World Study

NCT07410039 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT07410039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07410039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Eculizumab Add-On Therapy in the Acute Phase of Neuromyelitis Optica Spectrum Disorder: A Multicenter Prospective Real-World Study
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
February 1, 2026
Completion date
June 30, 2029
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuromyelitis optica spectrum disorder attack